Ansari, MA; Tripathi, T; Venkidasamy, B; Monziani, A; Rajakumar, G; Alomary, MN; Alyahya, SA; ... Thiruvengadam, M; + view all Ansari, MA; Tripathi, T; Venkidasamy, B; Monziani, A; Rajakumar, G; Alomary, MN; Alyahya, SA; Onimus, O; D’souza, N; Barkat, MA; Al-Suhaimi, EA; Samynathan, R; Thiruvengadam, M; - view fewer (2024) Multifunctional Nanocarriers for Alzheimer’s Disease: Befriending the Barriers. Molecular Neurobiology , 61 pp. 3042-3089. 10.1007/s12035-023-03730-z.

Text MOLN-D-23-00443_R2.pdf - Accepted Version Access restricted to UCL open access staff until 16 November 2024. Download (3MB)

Abstract

Neurodegenerative diseases (NDDs) have been increasing in incidence in recent years and are now widespread worldwide. Neuronal death is defined as the progressive loss of neuronal structure or function which is closely associated with NDDs and represents the intrinsic features of such disorders. Amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer’s, Parkinson’s, and Huntington’s diseases (AD, PD, and HD, respectively) are considered neurodegenerative diseases that affect a large number of people worldwide. Despite the testing of various drugs, there is currently no available therapy that can remedy or effectively slow the progression of these diseases. Nanomedicine has the potential to revolutionize drug delivery for the management of NDDs. The use of nanoparticles (NPs) has recently been developed to improve drug delivery efficiency and is currently subjected to extensive studies. Nanoengineered particles, known as nanodrugs, can cross the blood–brain barrier while also being less invasive compared to the most treatment strategies in use. Polymeric, magnetic, carbonic, and inorganic NPs are examples of NPs that have been developed to improve drug delivery efficiency. Primary research studies using NPs to cure AD are promising, but thorough research is needed to introduce these approaches to clinical use. In the present review, we discussed the role of metal-based NPs, polymeric nanogels, nanocarrier systems such as liposomes, solid lipid NPs, polymeric NPs, exosomes, quantum dots, dendrimers, polymersomes, carbon nanotubes, and nanofibers and surfactant-based systems for the therapy of neurodegenerative diseases. In addition, we highlighted nanoformulations such as N-butyl cyanoacrylate, poly(butyl cyanoacrylate), d-penicillamine, citrate-coated peptide, magnetic iron oxide, chitosan (CS), lipoprotein, ceria, silica, metallic nanoparticles, cholinesterase inhibitors, an acetylcholinesterase inhibitors, metal chelators, anti-amyloid, protein, and peptide-loaded NPs for the treatment of AD.

Download activity - last month

Export as JSONCSVXML

Download activity - last 12 months

Export as CSVXMLJSON

Downloads by country - last 12 months

Export as JSONCSVXML

Archive Staff Only

View Item